Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tripterygium wilfordii Hook F quadruple therapy in diabetic kidney disease
ChiCTR2400086105Phase 3Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Tripterygium wilfordii in diabetic glomerulosclerosis (2 arms), sponsored by Xijing Hospital. Primary endpoint: 24-hour urinary protein excretion. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
Tripterygium wilfordii
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2400086105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086105.